Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 10
2014 1
2015 3
2016 1
2017 6
2018 12
2019 16
2020 19
2021 19
2022 22
2023 15
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 31643619

95 results

Results by year

Filters applied: . Clear all
Page 1
Tildrakizumab.
[No authors listed] [No authors listed] 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643619 Free Books & Documents. Review.
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Khalilieh S, Hussain A, Montgomery D, Levine V, Shaw PM, Bodrug I, Mekokishvili L, Bailey-Smith C, Glasgow XS, Cheng A, Martinho M, Iwamoto M. Khalilieh S, et al. Br J Clin Pharmacol. 2018 Oct;84(10):2292-2302. doi: 10.1111/bcp.13670. Epub 2018 Jul 31. Br J Clin Pharmacol. 2018. PMID: 29926968 Free PMC article. Clinical Trial.
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations.
Galluzzo M, Chiricozzi A, Cinotti E, Brunasso G, Congedo M, Esposito M, Franchi C, Malara G, Narcisi A, Piaserico S, Tiberio R, Argenziano G, Fabbrocini G, Parodi A. Galluzzo M, et al. Expert Opin Biol Ther. 2022 Mar;22(3):367-376. doi: 10.1080/14712598.2022.1988566. Epub 2021 Oct 12. Expert Opin Biol Ther. 2022. PMID: 34607513 Free article.
Guselkumab.
[No authors listed] [No authors listed] 2018 Jun 26. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jun 26. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643594 Free Books & Documents. Review.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D. Reich K, et al. Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18. Br J Dermatol. 2020. PMID: 31218661 Free PMC article.
Tildrakizumab for the treatment of psoriasis.
Bangert C, Kopp T. Bangert C, et al. Immunotherapy. 2018 Sep;10(13):1105-1122. doi: 10.2217/imt-2018-0028. Epub 2018 Aug 7. Immunotherapy. 2018. PMID: 30081696 Review.
95 results